(+) Achillion: Oppenheimer Healthcare Conference (Achillion) - Dec 12, 2013 - "ACH-2684 proof of concept study"; "Significant antiviral activity demonstrated in GT1 patients"; "3 day proof of concept study evaluated treatment-naive HCV GT1 patients, either with and without cirrhosis: Significant antiviral activity demonstrated in HCV GT1 patients: Equivalent activity despite presence of cirrhosis; ACH-2684 was well tolerated in the study with no SAEs or patient discontinuations reported during treatment"
Clinical data • Hepatitis C Virus
|